New eye drug aims to restore vision in Diabetes-Related swelling

NCT ID NCT07705607

Not yet recruiting Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This phase 3 trial compares an experimental drug, MK-8748, to the standard treatment aflibercept for diabetic macular edema (DME), a condition where fluid buildup in the retina blurs vision. About 1,100 adults with diabetes and vision loss from DME receive either MK-8748 or aflibercept as eye injections. The main goal is to see if MK-8748 improves visual acuity as much as aflibercept over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called MK-8748 (also known as EYE201 or Tiespectus), given as an eye injection
What this could lead to: If MK-8748 works as well as or better than aflibercept, it could offer a new treatment option for people with diabetic macular edema who do not respond well to current therapies.
What could go wrong: This is a phase 3 trial, but MK-8748 is still experimental. It may not prove as effective as aflibercept, and eye injections carry risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema diabetic retinopathy Macular Edema macular retinal edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC RETINOPATHY MACULAR EDEMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.